The time-course of disease modifying effects of the neurotrophic factor inducer, PYM50028, in the MPTP-mouse model of Parkinson's disease

被引：0
|
作者：
Johnston, T. H.
Koprich, J. B.
Reyes, M. G.
Meyers, N. L.
Ward, C. L.
Hickling, R. I.
Howson, P. A.
Brotchie, J. M.
机构：
来源：
MOVEMENT DISORDERS | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1007
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [1] PYM50028, an orally active neurotrophic factor inducer, is neurorestorative following MPTP-administration in a mouse model of Parkinson's disease
    Johnston, T. H.
    Koprich, J. B.
    Brotchie, J. M.
    Howson, P. A.
    Orsi, A.
    MOVEMENT DISORDERS, 2009, 24 : S353 - S353
  • [2] PYM50028, a novel, orally active neurotrophic factor inducer, protects and reverses the neuronal damage induced by MPP+ in mesencephalic neuronal cultures and by MPTP in a mouse model of Parkinson's disease
    Visanji, N. P.
    Johnston, T. H.
    Callizot, N.
    Orsi, A.
    Rees, D.
    Brotchie, J. M.
    MOVEMENT DISORDERS, 2007, 22 : S18 - S18
  • [3] PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease
    Visanji, Naomi P.
    Orsi, Antonia
    Johnston, Tom H.
    Howson, Patrick A.
    Dixon, Kimberly
    Callizot, Noelle
    Brotchie, Jonathan M.
    Rees, Daryl D.
    FASEB JOURNAL, 2008, 22 (07): : 2488 - 2497
  • [4] PYM50028 restores dopamine transporter (DAT) levels in striatal dopamine terminals in a MPTP-lesioned mouse model of Parkinson's disease
    Visanji, N. P.
    Johnston, T. H.
    Brotchie, J. M.
    Hatton, S. L.
    Callizot, N.
    Orsi, A.
    Rees, D.
    MOVEMENT DISORDERS, 2006, 21 : S643 - S643
  • [5] Prior treatment with PYM50028, an orally active neurotrophic factor modulator in development for Parkinson's disease, reduces L-Dopa induced dyskinesia in MPTP-lesioned macaques
    Johnston, T. H.
    Fox, S. H.
    Howson, P. A.
    Brotchie, J. M.
    MOVEMENT DISORDERS, 2011, 26 : S281 - S282
  • [6] Cerebral alterations in a MPTP-mouse model of Parkinson's disease - an immunocytochemical study
    Muramatsu, Y
    Kurosaki, R
    Watanabe, H
    Michimata, M
    Matsubara, M
    Imai, Y
    Araki, T
    JOURNAL OF NEURAL TRANSMISSION, 2003, 110 (10) : 1129 - 1144
  • [7] Cerebral alterations in a MPTP-mouse model of Parkinson’s disease – an immunocytochemical study
    Y. Muramatsu
    R. Kurosaki
    H. Watanabe
    M. Michimata
    M. Matsubara
    Y. Imai
    T. Araki
    Journal of Neural Transmission, 2003, 110 : 1129 - 1144
  • [8] Neurorestorative efficacy of PYM50028 (Cogane™) in rodent and primate models of Parkinson's disease: Translation to dosing in humans
    Johnston, T. H.
    Fox, S. H.
    Koprich, J. B.
    Huot, P.
    Ward, C. L.
    Meyers, N.
    Howson, P. A.
    Brotchie, J. M.
    MOVEMENT DISORDERS, 2010, 25 (07) : S415 - S415
  • [9] TIME-COURSE STUDY OF NG2 GLIA ACTIVATION IN THE MPTP MOUSE MODEL OF PARKINSON'S DISEASE
    Liu, Y.
    Zhou, J.
    GLIA, 2013, 61 : S80 - S80
  • [10] Exercise induced behavioral recovery and plasticity in the MPTP-mouse model of Parkinson's disease
    Petzinger, G. M.
    Arevalo, P.
    Vuckovic, M.
    Turnquist, P.
    Hogg, E.
    Walsh, J.
    Akopian, G.
    Meshul, C.
    Abernathy, A.
    Ramirez, M.
    Fisher, B.
    Jakowec, M. W.
    MOVEMENT DISORDERS, 2006, 21 (09) : 1546 - 1546
12345